secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001837607-25-000021
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma advances ABP-450 biosimilar program, secures $20M funding
------------------------------------------------------------------------

- Pursuing 351(k) biosimilar pathway for ABP-450 with BOTOX as reference product for all therapeutic indications.
- Initiated primary analytical studies in Q4 2024; plans BPD Type 2a meeting with FDA in H2 2025.
- Closed $20M public offering in Jan 2025; ~89% of Series B warrants exercised as of March 21, 2025.
- No specific FY2024 financial results disclosed in the press release; focus on development and funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000021/0001837607-25-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000021/aeon-20250324x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-25-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer